Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

ADx NeuroSciences N.V.. (1/26/17). "Press Release: ADx NeuroSciences Receives 850.000 EUR Support from Flemish Government for Tracking Brain Disorders".

Region Region Flanders (Flemish region)
  Country Belgium
Organisations Organisation ADx NeuroSciences S.A. / N.V.
  Organisation 2 VLAIO (Flanders Innovation & Entrepreneurship, Agentschap Innoveren & Ondernemen)
  Group Flanders (govt)
Products Product Alzheimer test (blood)
  Product 2 business development (state/region)
Index term Index term ADx NeuroSciences–Flanders (govt): grant, 201701–201812 grant €850k to develop blood test for neurogenerative diseases
Person Person Dewaele, Koen (ADx NeuroSciences 201701 CEO)

Brain injuries, dementia and other neurological problems are often noticed too late. The damage is irrevocable. ADX Neurosciences S.A. is committed to developing biomarkers that can detect, with a simple blood test, neurodegeneration in an early stage. The Flemish government supports the innovative research of this biotech company.

With the grant of 850,000 euros ADX can expand its global leadership position as an innovator in the field of neurobiological markers.

In what way will ADx use the money from the Flemish Government over the next two years?

1. The fine-tuning of a blood test that can detect neurodegeneration in an early stage
2. Exploring a new development platform to significantly shorten the time between discovery of a marker and its commercialization
3. The detection and discovery of new markers that play a crucial role in the faltering communication between brain cells

Why does the Flemish Government support this innovative company?

In only 5 years, ADx acquired a good global position in the challenging field of brain diseases such as Alzheimer's and Parkinson's. ADX has also managed to launch, with a previous grant, two new markers, neurogranin and BACE1, in collaboration with Prof. Bart De Strooper (KU Leuven - VIB) and Prof. Sebastiaan Engelborghs (UA). Both of these tests will play an important role in the development of new drugs for Alzheimer's disease. The Flemish Agency for Enterprise and Innovation (VLAIO) also gave the green light to this new, ambitious project.

Koen Dewaele, CEO ADX: "We are very pleased with this support! This strengthens our ambition to build a world-neurobiological company. Our new tests will help a better and quicker diagnosis and also assist pharmaceutical companies in their development of new drugs for neurological disorders such as Alzheimer's, Parkinson's and ALS. "

For more information, contact:
Koen Dewaele, CEO ADx NeuroSciences
GSM: +32 4 78 88 87 05
tel.: +32 9 261 69 82

Record changed: 2023-06-05


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top